Does RAVULIZUMAB-CWVZ Cause Breakthrough haemolysis? 120 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 120 reports of Breakthrough haemolysis have been filed in association with RAVULIZUMAB-CWVZ. This represents 1.2% of all adverse event reports for RAVULIZUMAB-CWVZ.
120
Reports of Breakthrough haemolysis with RAVULIZUMAB-CWVZ
1.2%
of all RAVULIZUMAB-CWVZ reports
0
Deaths
22
Hospitalizations
How Dangerous Is Breakthrough haemolysis From RAVULIZUMAB-CWVZ?
Of the 120 reports, 22 (18.3%) required hospitalization.
Is Breakthrough haemolysis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RAVULIZUMAB-CWVZ. However, 120 reports have been filed with the FAERS database.
What Other Side Effects Does RAVULIZUMAB-CWVZ Cause?
Fatigue (1,472)
Asthenia (727)
Headache (639)
Drug ineffective (570)
Off label use (451)
Muscular weakness (422)
Dyspnoea (414)
Malaise (353)
Haemoglobin decreased (346)
Myasthenia gravis (338)
What Other Drugs Cause Breakthrough haemolysis?
Which RAVULIZUMAB-CWVZ Alternatives Have Lower Breakthrough haemolysis Risk?
RAVULIZUMAB-CWVZ vs REBAMIPIDE
RAVULIZUMAB-CWVZ vs REBETOL
RAVULIZUMAB-CWVZ vs REBIF
RAVULIZUMAB-CWVZ vs REBOXETINE
RAVULIZUMAB-CWVZ vs RECLAST